characteristics | Number (48 patients) | % |
Age |
|
|
(Mean ± SD) | 56.8 ± 10.8 |
|
Median (range) | 57 (29 - 75) |
|
Sex |
|
|
Male | 33 | 68.8% |
Female | 15 | 31.2% |
ECOG performance status |
|
|
0 | 1 | 2.1% |
1 | 28 | 58.3% |
2 | 19 | 39.6% |
Pathology |
|
|
squamous cell carcinoma | 18 | 37.5% |
adenocarcinoma | 18 | 37.5% |
Others | 12 | 25% |
T Stage |
|
|
1 | 4 | 8.3% |
2 | 16 | 33.3% |
3 | 20 | 41.7% |
4 | 8 | 16.7% |
N Stage |
|
|
1 | 9 | 18.8% |
2 | 19 | 39.6% |
3 | 14 | 29.2% |
4 | 6 | 12.5% |
Response to chemotherapy |
|
|
Partial | 20 | 41.7% |
Stationary | 28 | 58.3% |
Number of metastasis |
|
|
1 | 3 | 6.3% |
2 | 11 | 22.9% |
3 | 19 | 39.6% |
4 | 10 | 20.8% |
5 | 5 | 10.4% |
EGFR |
|
|
Negative | 15 | 31.3% |
Positive | 5 | 10.4% |
Not applicable | 28 | 58.3% |
ALK |
|
|
Negative | 19 | 39.6% |
Positive | 1 | 2.1% |
Not applicable | 28 | 58.3% |
CNS metastasis |
|
|
Yes | 11 | 22.9% |
No | 37 | 77.1% |
Site of metastasis |
|
|
Single organ | 19 | 39.6% |
Multiple organ | 29 | 60.4% |